Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Descending)
62756-0238-86 62756-0238 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0238-88 62756-0238 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0239-18 62756-0239 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0239-20 62756-0239 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0239-83 62756-0239 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
63020-0536-30 63020-0536 ponatinib hydrochloride Iclusig 10.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 11, 2021 In Use
63304-0095-11 63304-0095 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0095-30 63304-0095 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0096-11 63304-0096 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0096-30 63304-0096 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0135-11 63304-0135 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0135-30 63304-0135 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63323-0825-20 63323-0825 Decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 2, 2019 In Use
63759-3028-01 63759-3028 gemcitabine GEMCITABINE 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous June 19, 2019 In Use
63759-3029-01 63759-3029 gemcitabine GEMCITABINE 1.0 g/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous June 19, 2019 In Use
68001-0488-07 68001-0488 CAPECITABINE CAPECITABINE 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 22, 2021 In Use
68083-0337-01 68083-0337 Cytarabine Cytarabine 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous Dec. 23, 2019 In Use
68083-0343-05 68083-0343 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous Dec. 23, 2019 In Use
72485-0213-15 72485-0213 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Sept. 4, 2020 In Use
68083-0382-01 68083-0382 Irinotecan hydrochloride Irinotecan hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
70700-0170-22 70700-0170 Irinotecan hydrochloride Irinotecan hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
68083-0259-01 68083-0259 Melphalan hydrochloride Melphalan hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 10, 2019 In Use
68001-0389-36 68001-0389 Mitomycin Mitomycin 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 14, 2019 In Use
68001-0390-77 68001-0390 Mitomycin Mitomycin 20.0 mg/40mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 14, 2019 In Use
68001-0391-79 68001-0391 Mitomycin Mitomycin 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 14, 2019 In Use
67184-0501-01 67184-0501 Oxaliplatin Oxaliplatin 50.0 mg/10mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 11, 2016 In Use
67184-0502-01 67184-0502 Oxaliplatin Oxaliplatin 100.0 mg/20mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 11, 2016 In Use
68001-0468-36 68001-0468 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Dec. 9, 2020 In Use
68001-0468-37 68001-0468 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Dec. 9, 2020 In Use
65219-0200-05 65219-0200 Temsirolimus Temsirolimus Chemotherapy Enzyme Inhibitor mTOR Intravenous Nov. 20, 2020 In Use
68083-0202-01 68083-0202 Temsirolimus Injection Temsirolimus Chemotherapy Enzyme Inhibitor mTOR Intravenous Aug. 26, 2019 In Use
68001-0490-05 68001-0490 imatinib mesylate imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 26, 2021 In Use
68180-0801-36 68180-0801 lapatinib Lapatinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Sept. 29, 2020 In Use
16729-0295-12 16729-0295 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound INTRACAVERNOUS, Intravenous Oct. 3, 2017 In Use
16729-0295-31 16729-0295 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound INTRACAVERNOUS, Intravenous Sept. 19, 2017 In Use
16729-0295-33 16729-0295 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound INTRACAVERNOUS, Intravenous Sept. 19, 2017 In Use
16729-0295-34 16729-0295 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound INTRACAVERNOUS, Intravenous Sept. 19, 2017 In Use
00173-0898-03 00173-0898 dostarlimab Jemperli 50.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous April 22, 2021 In Use
00121-0902-04 00121-0902 Prednisolone Sodium Phosphate Prednisolone Sodium Phosphate 5.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 10, 2021 In Use
00143-9092-01 00143-9092 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jan. 19, 2018 In Use
00143-9093-01 00143-9093 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jan. 19, 2018 In Use
00143-9428-01 00143-9428 FOSAPREPITANT DIMEGLUMINE FOSAPREPITANT DIMEGLUMINE 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous May 1, 2021 In Use
16714-0159-01 16714-0159 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 6, 2021 In Use
00904-7144-61 00904-7144 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 3, 2021 In Use
00904-7145-04 00904-7145 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 3, 2021 In Use
16714-0160-01 16714-0160 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 6, 2021 In Use
16714-0200-30 16714-0200 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 27, 2021 In Use
16714-0201-10 16714-0201 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 27, 2021 In Use
16714-0201-30 16714-0201 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 27, 2021 In Use
42806-0358-01 42806-0358 Leucovorin Calcium Leucovorin Calcium 5.0 mg/1 Ancillary Therapy Chemoprotective Antidote Oral April 16, 2020 In Use

Found 10,000 results in 6 millisecondsExport these results